Blood dyscrasia with quetiapine and ziprasidone.
Nair
Preetha
P
Lippmann
Steven
S
D000284:Administration, Oral; D000328:Adult; D000748:Anemia, Macrocytic / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects; D003987:Dibenzothiazepines / Q000627:therapeutic use / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D013287:Illicit Drugs / Q000633:toxicity*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity*; D011605:Psychoses, Substance-Induced / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D019966:Substance-Related Disorders / Q000150:complications*; D013844:Thiazoles / Q000627:therapeutic use / Q000633:toxicity*
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D013287:Illicit Drugs; D010879:Piperazines; D013844:Thiazoles; D000069348:Quetiapine Fumarate; C092292:ziprasidone